Company / R&D Expense
KYNTRA BIO, INC. R&D Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$95.7M
FY2025
5-year range
$95.7M / $387.0M
FY2021-FY2025
Trend
-64.1%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
R&D Expense has fluctuated over the past 10 years, ranging from $96M in FY2025 to $387M in FY2023.
Based on SEC 10-K filings.
$96M in FY2025 with a 5-year CAGR of -16.5%.
Declined from $387M to $96M over the past 2 years.
R&D Expense over time
Growth rates
- 3-Year CAGR
- -27.7%
- 5-Year CAGR
- -16.5%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of -16.5%, indicating a declining trend.
- In FY2025, r&d expense decreased 64.1% year-over-year.
- Peak r&d expense was recorded in FY2023.
Company context
Key Data Points
- Altman Z-Score -3.33 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $95.7M | -64.1% |
| FY2024 | $266.5M | -31.2% |
| FY2023 | $387.0M | +53.0% |
| FY2022 | $252.9M | +20.9% |
| FY2021 | $209.3M | -11.3% |
| FY2020 | $235.8M | +20.0% |
| FY2019 | $196.5M | +5.0% |
| FY2018 | $187.2M | -12.6% |
| FY2017 | $214.1M | +42.0% |
| FY2016 | $150.8M | +75.9% |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026